SE0301998D0 - Quil A fraction with low toxicity and use thereof - Google Patents
Quil A fraction with low toxicity and use thereofInfo
- Publication number
- SE0301998D0 SE0301998D0 SE0301998A SE0301998A SE0301998D0 SE 0301998 D0 SE0301998 D0 SE 0301998D0 SE 0301998 A SE0301998 A SE 0301998A SE 0301998 A SE0301998 A SE 0301998A SE 0301998 D0 SE0301998 D0 SE 0301998D0
- Authority
- SE
- Sweden
- Prior art keywords
- quil
- fraction
- adjuvant
- lps
- derivatives
- Prior art date
Links
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 title abstract 3
- 231100000053 low toxicity Toxicity 0.000 title 1
- 239000002671 adjuvant Substances 0.000 abstract 4
- 229930182490 saponin Natural products 0.000 abstract 4
- 150000007949 saponins Chemical class 0.000 abstract 4
- 235000017709 saponins Nutrition 0.000 abstract 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 2
- 108010039939 Cell Wall Skeleton Proteins 0.000 abstract 1
- 108010028921 Lipopeptides Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 210000004520 cell wall skeleton Anatomy 0.000 abstract 1
- 210000003918 fraction a Anatomy 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Priority Applications (22)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0301998A SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Quil A fraction with low toxicity and use thereof |
| AU2004254152A AU2004254152B2 (en) | 2003-07-07 | 2004-07-07 | Quil a fraction with low toxicity and use thereof |
| BRPI0412444A BRPI0412444B8 (pt) | 2003-07-07 | 2004-07-07 | fração de quil a com baixa toxidez e seu uso |
| ES04749076T ES2331952T3 (es) | 2003-07-07 | 2004-07-07 | Fraccion de quil a con baja toxicidad y su uso. |
| JP2006518582A JP4731475B2 (ja) | 2003-07-07 | 2004-07-07 | 毒性の低いＱｕｉｌＡ画分およびその使用 |
| NZ544299A NZ544299A (en) | 2003-07-07 | 2004-07-07 | Quil A fraction A for the enhancement of immune activities and immunomodulating activities |
| DE602004023089T DE602004023089D1 (de) | 2003-07-07 | 2004-07-07 | Quil a fraktion mit geringer toxizität und ihre verwendung |
| EP04749076A EP1648505B1 (fr) | 2003-07-07 | 2004-07-07 | Fraction de quil a a faible toxicite, utilisation de cette derniere |
| US10/562,866 US8821881B2 (en) | 2003-07-07 | 2004-07-07 | Quil A fraction with low toxicity and use thereof |
| AT04749076T ATE442164T1 (de) | 2003-07-07 | 2004-07-07 | Quil a fraktion mit geringer toxizität und ihre verwendung |
| CA2529363A CA2529363C (fr) | 2003-07-07 | 2004-07-07 | Fraction de quil a a faible toxicite, utilisation de cette derniere |
| PCT/SE2004/001038 WO2005002620A1 (fr) | 2003-07-07 | 2004-07-07 | Fraction de quil a a faible toxicite, utilisation de cette derniere |
| PL04749076T PL1648505T3 (pl) | 2003-07-07 | 2004-07-07 | Frakcja Quil A o niskiej toksyczności i jej zastosowanie |
| DK04749076T DK1648505T3 (da) | 2003-07-07 | 2004-07-07 | Quil A-fraktion med lav toksicitet og anvendelse deraf |
| ZA200600151A ZA200600151B (en) | 2003-07-07 | 2006-01-06 | Quil A fraction with low toxicity and use thereof |
| US14/445,690 US20140335049A1 (en) | 2003-07-07 | 2014-07-29 | Quil a fraction with low toxicity and use thereof |
| US14/714,664 US20150320858A1 (en) | 2003-07-07 | 2015-05-18 | Quil a fraction with low toxicity and use thereof |
| US15/054,801 US20160184427A1 (en) | 2003-07-07 | 2016-02-26 | Quil a fraction with low toxicity and use thereof |
| US15/874,262 US20180369368A1 (en) | 2003-07-07 | 2018-01-18 | Quil a fraction with low toxicity and use thereof |
| US16/701,948 US20200345840A1 (en) | 2003-07-07 | 2019-12-03 | Quil a fraction with low toxicity and use thereof |
| US17/477,739 US20220241408A1 (en) | 2003-07-07 | 2021-09-17 | Quil a fraction with low toxicity and use thereof |
| US18/376,666 US12171828B2 (en) | 2003-07-07 | 2023-10-04 | Quil A fraction with low toxicity and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0301998A SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Quil A fraction with low toxicity and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE0301998D0 true SE0301998D0 (sv) | 2003-07-07 |
Family
ID=27731119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE0301998A SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Quil A fraction with low toxicity and use thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (8) | US8821881B2 (fr) |
| EP (1) | EP1648505B1 (fr) |
| JP (1) | JP4731475B2 (fr) |
| AT (1) | ATE442164T1 (fr) |
| AU (1) | AU2004254152B2 (fr) |
| BR (1) | BRPI0412444B8 (fr) |
| CA (1) | CA2529363C (fr) |
| DE (1) | DE602004023089D1 (fr) |
| DK (1) | DK1648505T3 (fr) |
| ES (1) | ES2331952T3 (fr) |
| NZ (1) | NZ544299A (fr) |
| PL (1) | PL1648505T3 (fr) |
| SE (1) | SE0301998D0 (fr) |
| WO (1) | WO2005002620A1 (fr) |
| ZA (1) | ZA200600151B (fr) |
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1104306E (pt) * | 1998-08-10 | 2006-05-31 | Antigenics Inc | Composicoes de cpg e adjuvantes de saponina e seus metodos |
| SE0202110D0 (sv) * | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
| SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
| US8007806B2 (en) | 2005-01-20 | 2011-08-30 | Isconova Ab | Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide |
| EP1764369A1 (fr) * | 2005-09-16 | 2007-03-21 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Vaccins comprenant la protéine du noyau du HBV tronquée ainsi qu'un adjuvant à base de saponine |
| CN101448523A (zh) | 2006-03-24 | 2009-06-03 | 诺华疫苗和诊断有限两合公司 | 无需冷藏储存流感疫苗 |
| PT2054431E (pt) | 2006-06-09 | 2011-11-03 | Novartis Ag | Confórmeros de adesinas bacterianas |
| EP1902727A1 (fr) * | 2006-09-22 | 2008-03-26 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Vaccins comprenant la protéine du noyau du HBV tronquée ainsi qu'un adjuvant à base de saponine |
| WO2008031878A1 (fr) * | 2006-09-15 | 2008-03-20 | Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH | Composition pour la thérapie et/ou pour la prophylaxie d'infections au vhb et de maladies dont la médiation est assurée par le vhb |
| DK2094278T3 (en) * | 2006-11-20 | 2017-07-24 | Duecom | USE OF LIPID-CONTAINING PARTICLES INCLUDING QUILLAJA SAPONINS FOR CANCER TREATMENT |
| KR20100045437A (ko) | 2007-06-27 | 2010-05-03 | 노파르티스 아게 | 첨가물이 적은 인플루엔자 백신 |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| ES2569907T3 (es) | 2008-06-27 | 2016-05-13 | Zoetis Services Llc | Composiciones adyuvantes novedosas |
| CN102470168A (zh) * | 2009-07-10 | 2012-05-23 | 伊斯克诺瓦公司 | 新组合物 |
| US8771709B2 (en) | 2010-09-20 | 2014-07-08 | Crucell Holland B.V. | Therapeutic vaccination against active Tuberculosis |
| DK2750683T4 (da) * | 2011-10-03 | 2021-04-12 | Croda Int Plc | Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser |
| EP3566714A1 (fr) | 2011-11-28 | 2019-11-13 | Janssen Vaccines & Prevention B.V. | Vaccins contre la grippe et utilisations associées |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| SI2825640T1 (sl) | 2012-03-12 | 2016-08-31 | Crucell Holland B.V. | Šarže rekombinantnega adenovirusa s spremenjenimi konci |
| JP5805908B2 (ja) | 2012-03-22 | 2015-11-10 | クルセル ホランド ベー ヴェー | Ｒｓｖに対するワクチン |
| US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
| US11576958B2 (en) | 2013-02-07 | 2023-02-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
| WO2014135651A1 (fr) | 2013-03-08 | 2014-09-12 | Crucell Holland B.V. | Vaccin acellulaire contre la coqueluche |
| AR095962A1 (es) | 2013-04-01 | 2015-11-25 | Moreinx Ab | Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos |
| KR102236497B1 (ko) | 2013-04-25 | 2021-04-06 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드 |
| EA034639B1 (ru) | 2013-05-30 | 2020-03-02 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцины против вируса гриппа и их применения |
| CN105408348B (zh) | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| WO2015000831A1 (fr) | 2013-07-02 | 2015-01-08 | Crucell Holland B.V. | Procédé pour la préparation de virosomes |
| WO2015000832A1 (fr) | 2013-07-02 | 2015-01-08 | Crucell Holland B.V. | Procédé de préparation de virosomes |
| UA130246C2 (uk) | 2013-09-19 | 2025-12-31 | Зоетіс Сервісіз Ллс | Ад'ювант на основі олії |
| DE102014005771A1 (de) | 2014-04-23 | 2015-10-29 | Clariant International Ltd. | Verwendung von wässrigen driftreduzierenden Zusammensetzungen |
| MX378904B (es) | 2014-07-10 | 2025-03-10 | Janssen Vaccines & Prevention Bv | Vacunas para virus influenza y usos de las mismas. |
| RS58080B1 (sr) | 2014-11-04 | 2019-02-28 | Janssen Vaccines & Prevention Bv | Terapeutske vakcine protiv hpv16 |
| CN115317600A (zh) | 2015-01-16 | 2022-11-11 | 硕腾服务有限责任公司 | 口蹄疫疫苗 |
| JP6735288B2 (ja) | 2015-04-14 | 2020-08-05 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 双方向性プロモーターを有する２つの導入遺伝子を発現する組換えアデノウイルス |
| EA039065B1 (ru) | 2015-07-07 | 2021-11-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
| US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| JP6470872B2 (ja) | 2015-08-20 | 2019-02-13 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 治療用ｈｐｖ１８ワクチン |
| US10538557B2 (en) | 2015-09-02 | 2020-01-21 | Janssen Vaccines & Prevention B.V. | Stabilized viral class I fusion proteins |
| CA2996007A1 (fr) | 2015-09-03 | 2017-03-09 | Novavax, Inc. | Compositions vaccinales ayant une stabilite et une immunogenicite ameliorees |
| RU2723039C2 (ru) | 2015-12-23 | 2020-06-08 | Пфайзер Инк. | Мутанты белка f rsv |
| JP7233928B2 (ja) | 2016-04-05 | 2023-03-07 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Ｒｓｖに対するワクチン |
| IL262108B2 (en) | 2016-04-05 | 2023-04-01 | Janssen Vaccines Prevention B V | Soluble pre-fusion rsv f proteins are stabilized |
| JP7053491B2 (ja) | 2016-05-02 | 2022-04-12 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 治療用ｈｐｖワクチン組み合わせ |
| DE202016003070U1 (de) | 2016-05-09 | 2016-06-07 | Clariant International Ltd. | Stabilisatoren für Silikatfarben |
| CN109154000B (zh) | 2016-05-12 | 2022-07-05 | 扬森疫苗与预防公司 | 有效和平衡的双向启动子 |
| WO2017207477A1 (fr) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Protéines f du vrs de pré-fusion solubles stabilisées |
| CN109311946A (zh) | 2016-05-30 | 2019-02-05 | 扬森疫苗与预防公司 | 稳定化的融合前rsv f蛋白 |
| RU2745500C2 (ru) | 2016-06-20 | 2021-03-25 | Янссен Вэксинс Энд Превеншн Б.В. | Эффективный и сбалансированный двунаправленный промотор |
| WO2018011196A1 (fr) | 2016-07-14 | 2018-01-18 | Janssen Vaccines & Prevention B.V. | Vaccins contre le hpv |
| CN109906411B (zh) | 2016-11-04 | 2022-12-27 | 卡博特公司 | 含结晶聚酯和有机硅的纳米复合物 |
| US11034978B2 (en) | 2017-02-09 | 2021-06-15 | Janssen Vaccines & Prevention B.V. | Potent and short promoter for expression of heterologous genes |
| AU2018267971A1 (en) | 2017-05-17 | 2019-11-07 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
| JP7317796B2 (ja) | 2017-07-24 | 2023-07-31 | ノババックス，インコーポレイテッド | 呼吸器疾患を治療するための方法および組成物 |
| SG11202001458SA (en) | 2017-09-15 | 2020-03-30 | Janssen Vaccines & Prevention Bv | Method for the safe induction of immunity against rsv |
| LT3743106T (lt) | 2018-01-23 | 2022-09-26 | Janssen Vaccines & Prevention B.V. | Gripo viruso vakcinos ir jų panaudojimo būdai |
| CN120227451A (zh) | 2018-03-19 | 2025-07-01 | 诺瓦瓦克斯股份有限公司 | 多价流感纳米颗粒疫苗 |
| GB201807303D0 (en) | 2018-05-03 | 2018-06-20 | London School Of Hygeine & Tropical Medicine | Glyconjugate vaccines |
| CA3098103A1 (fr) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Adjuvant moleculaire |
| MX2021005607A (es) | 2018-11-13 | 2021-06-30 | Janssen Vaccines & Prevention Bv | Proteinas f de prefusion del vrs estabilizadas. |
| US20220204567A1 (en) | 2019-04-25 | 2022-06-30 | Janssen Vaccines & Prevention B.V. | Recombinant influenza antigens |
| JP2022532742A (ja) | 2019-05-15 | 2022-07-19 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | アデノウイルスベースのワクチンによる呼吸器合胞体ウイルス感染の予防的処置 |
| WO2020229577A1 (fr) | 2019-05-15 | 2020-11-19 | Janssen Vaccines & Prevention B.V. | Co-administration d'un vaccin contre la grippe saisonnière et vaccin contre le virus respiratoire syncytial à base d'adénovirus |
| CA3152957A1 (fr) | 2019-09-05 | 2021-03-11 | Janssen Vaccines & Prevention B.V. | Vaccins contre le virus de la grippe et leurs utilisations |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| KR20230009466A (ko) | 2020-05-11 | 2023-01-17 | 얀센 파마슈티칼즈, 인코포레이티드 | SARS-CoV-2 백신 |
| CA3183086A1 (fr) | 2020-05-11 | 2021-11-18 | Janssen Pharmaceuticals, Inc. | Proteines de fusion de proteine de spicule de coronavirus stabilisees |
| WO2021229448A1 (fr) | 2020-05-11 | 2021-11-18 | Janssen Pharmaceuticals, Inc. | Réplicon d'arn codant pour une protéine de spicule de coronavirus stabilisée |
| US20230233661A1 (en) | 2020-06-29 | 2023-07-27 | Janssen Vaccines & Prevention B.V. | Vaccine combination against repiratory syncytial virus infection |
| US20230302119A1 (en) | 2020-07-06 | 2023-09-28 | Janssen Pharmaceuticals, Inc. | Stabilized Corona Virus Spike Protein Fusion Proteins |
| JP7822149B2 (ja) | 2020-10-02 | 2026-03-02 | ファイザー・インク | Ｒｓｖ ｆタンパク質生産のための細胞培養工程 |
| WO2022175479A1 (fr) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Associations de vaccins contre les infections par les souches a et b du virus respiratoire syncytial |
| WO2022175477A1 (fr) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Antigènes fb de vrs de pré-fusion stabilisés |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| KR20230165275A (ko) | 2021-04-01 | 2023-12-05 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 융합 전 piv3 f 단백질 |
| WO2023020939A1 (fr) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Vaccins contre le sars-cov-2 |
| WO2023047348A1 (fr) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Protéines de fusion de protéine de spicule de coronavirus stabilisées |
| WO2023047349A1 (fr) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Protéines de fusion protéines de spicule de coronavirus stabilisées |
| WO2023111725A1 (fr) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Vaccins anti-sars-cov-2 |
| EP4448802A1 (fr) | 2021-12-16 | 2024-10-23 | Janssen Vaccines & Prevention B.V. | Protéines de fusion hmpv pré-hybrides stabilisées |
| WO2023196634A2 (fr) | 2022-04-08 | 2023-10-12 | Flagship Pioneering Innovations Vii, Llc | Vaccins et procédés associés |
| KR20250010642A (ko) | 2022-05-12 | 2025-01-21 | 엠에스디 인터내셔널 비즈니스 게엠베하 | 안정화된 융합-전 hmpv 융합 단백질 |
| WO2024017682A1 (fr) | 2022-07-18 | 2024-01-25 | Janssen Vaccines & Prevention B.V. | Immunogènes du vrs |
| EP4565604A2 (fr) | 2022-08-01 | 2025-06-11 | Flagship Pioneering Innovations VII, LLC | Protéines immunomodulatrices et méthodes associées |
| WO2024061757A1 (fr) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Protéines f du piv1 humain en pré-fusion |
| WO2024061759A1 (fr) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Protéines s de coronavirus stabilisées |
| WO2024061753A1 (fr) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Protéines de fusion de classe i trimères stabilisées |
| WO2024074584A1 (fr) | 2022-10-06 | 2024-04-11 | Janssen Vaccines & Prevention B.V. | Protéines f du piv3 sous forme pré-fusion stabilisées |
| CN120202213A (zh) | 2022-11-14 | 2025-06-24 | 扬森疫苗与预防有限公司 | 乙型流感病毒疫苗及其用途 |
| WO2024151583A2 (fr) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations Vii, Llc | Vaccins et procédés associés |
| US20240252614A1 (en) | 2023-01-18 | 2024-08-01 | Pfizer Inc. | Vaccines against respiratory diseases |
| WO2024167885A1 (fr) | 2023-02-06 | 2024-08-15 | Flagship Pioneering Innovations Vii, Llc | Compositions immunomodulatrices et procédés associés |
| KR20250152090A (ko) | 2023-02-21 | 2025-10-22 | 엠에스디 인터내셔널 비즈니스 게엠베하 | 이종 삼량체화 도메인이 없는 안정화된 삼량체 rsv 융합 단백질 |
| WO2024258829A1 (fr) | 2023-06-12 | 2024-12-19 | Flagship Pioneering Innovations Vii, Llc | Compositions de vaccin contre le sars-cov-2 et procédés associés |
| TW202545974A (zh) | 2024-01-26 | 2025-12-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 免疫受體抑制蛋白及相關方法 |
| WO2025163460A2 (fr) | 2024-01-30 | 2025-08-07 | Pfizer Inc. | Vaccins contre des maladies respiratoires |
| US20250353881A1 (en) | 2024-05-16 | 2025-11-20 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor inhibitory proteins and related methods |
| WO2025245111A1 (fr) | 2024-05-22 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Protéines de ciblage d'immunorécepteurs et procédés associés |
| WO2026018181A1 (fr) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Compositions immunogènes et leurs utilisations |
| WO2026038177A1 (fr) | 2024-08-16 | 2026-02-19 | Pfizer Inc. | Compositions immunogènes et leurs utilisations |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5839376B2 (ja) * | 1978-10-30 | 1983-08-30 | 富士通株式会社 | イオン注入法 |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| ATE71303T1 (de) | 1986-01-14 | 1992-01-15 | Nederlanden Staat | Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung. |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| CA1331443C (fr) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Adjuvant a saponine |
| NZ230747A (en) * | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| NL9002314A (nl) | 1990-10-23 | 1992-05-18 | Nederlanden Staat | Immunogene complexen, in het bijzonder iscoms. |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| SE9600647D0 (sv) | 1996-02-21 | 1996-02-21 | Bror Morein | Ny användning |
| US6231859B1 (en) | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
| AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
| US6558670B1 (en) * | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
| SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
| SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
-
2003
- 2003-07-07 SE SE0301998A patent/SE0301998D0/xx unknown
-
2004
- 2004-07-07 BR BRPI0412444A patent/BRPI0412444B8/pt active IP Right Grant
- 2004-07-07 EP EP04749076A patent/EP1648505B1/fr not_active Expired - Lifetime
- 2004-07-07 ES ES04749076T patent/ES2331952T3/es not_active Expired - Lifetime
- 2004-07-07 WO PCT/SE2004/001038 patent/WO2005002620A1/fr not_active Ceased
- 2004-07-07 JP JP2006518582A patent/JP4731475B2/ja not_active Expired - Lifetime
- 2004-07-07 AT AT04749076T patent/ATE442164T1/de not_active IP Right Cessation
- 2004-07-07 PL PL04749076T patent/PL1648505T3/pl unknown
- 2004-07-07 CA CA2529363A patent/CA2529363C/fr not_active Expired - Lifetime
- 2004-07-07 DE DE602004023089T patent/DE602004023089D1/de not_active Expired - Lifetime
- 2004-07-07 US US10/562,866 patent/US8821881B2/en active Active
- 2004-07-07 NZ NZ544299A patent/NZ544299A/en not_active IP Right Cessation
- 2004-07-07 AU AU2004254152A patent/AU2004254152B2/en not_active Expired
- 2004-07-07 DK DK04749076T patent/DK1648505T3/da active
-
2006
- 2006-01-06 ZA ZA200600151A patent/ZA200600151B/en unknown
-
2014
- 2014-07-29 US US14/445,690 patent/US20140335049A1/en not_active Abandoned
-
2015
- 2015-05-18 US US14/714,664 patent/US20150320858A1/en not_active Abandoned
-
2016
- 2016-02-26 US US15/054,801 patent/US20160184427A1/en not_active Abandoned
-
2018
- 2018-01-18 US US15/874,262 patent/US20180369368A1/en not_active Abandoned
-
2019
- 2019-12-03 US US16/701,948 patent/US20200345840A1/en not_active Abandoned
-
2021
- 2021-09-17 US US17/477,739 patent/US20220241408A1/en not_active Abandoned
-
2023
- 2023-10-04 US US18/376,666 patent/US12171828B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20150320858A1 (en) | 2015-11-12 |
| DK1648505T3 (da) | 2009-12-21 |
| PL1648505T3 (pl) | 2010-02-26 |
| ATE442164T1 (de) | 2009-09-15 |
| US20220241408A1 (en) | 2022-08-04 |
| US20160184427A1 (en) | 2016-06-30 |
| CA2529363A1 (fr) | 2005-01-13 |
| JP4731475B2 (ja) | 2011-07-27 |
| BRPI0412444B1 (pt) | 2016-06-14 |
| US8821881B2 (en) | 2014-09-02 |
| AU2004254152A1 (en) | 2005-01-13 |
| US20200345840A1 (en) | 2020-11-05 |
| US12171828B2 (en) | 2024-12-24 |
| EP1648505A1 (fr) | 2006-04-26 |
| BRPI0412444A (pt) | 2006-09-19 |
| ES2331952T3 (es) | 2010-01-21 |
| DE602004023089D1 (de) | 2009-10-22 |
| US20140335049A1 (en) | 2014-11-13 |
| WO2005002620A1 (fr) | 2005-01-13 |
| AU2004254152B2 (en) | 2009-10-29 |
| JP2007527386A (ja) | 2007-09-27 |
| US20060239963A1 (en) | 2006-10-26 |
| EP1648505B1 (fr) | 2009-09-09 |
| ZA200600151B (en) | 2007-01-31 |
| US20240024468A1 (en) | 2024-01-25 |
| NZ544299A (en) | 2009-03-31 |
| US20180369368A1 (en) | 2018-12-27 |
| CA2529363C (fr) | 2013-04-02 |
| BRPI0412444B8 (pt) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE0301998D0 (sv) | Quil A fraction with low toxicity and use thereof | |
| MX393384B (es) | Adyuvantes sinteticos de glucopiranosil-lipido. | |
| BRPI0619795B8 (pt) | composição imunogênica, composição adjuvante, e, uso de uma composição imunogênica e um adjuvante | |
| UA94900C2 (uk) | Вакцина | |
| PT1187629E (pt) | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador | |
| MX2010001054A (es) | Composiciones adyuvantes antigenicas y metodos. | |
| WO2007109812A3 (fr) | Composes de potentialisation immunitaire | |
| MY137619A (en) | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | |
| WO2006086449A3 (fr) | Thiazoloquinolines et thiazolonaphthyridines a substitution alcoxy | |
| MX2007003078A (es) | Compuestos de imidazoquinolina. | |
| SI2068918T1 (sl) | Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala | |
| NO20064781L (no) | Fremgangsmater og adjuvanser for a forbedre immunresponser mot vaksiner og fremgangsmater for anvendelse | |
| BRPI0621181A8 (pt) | Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico | |
| AR044696A1 (es) | Composicion de vacunas | |
| NO20070746L (no) | Anvendelse av fosfaterte alkanoler som dispergente , emulgatorer, hydrotroper, fuktmidler og kompatabilitetsstoffer i blandinger for jordbruket. | |
| BRPI0511026A (pt) | uso de um los neisserial, e, composição | |
| WO2016179034A3 (fr) | Procédés et compositions permettant de stimuler une réponse immunitaire à l'aide de motifs d'arn immunostimulateurs puissants | |
| AU5162201A (en) | Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21 | |
| EP1905449A3 (fr) | Composition adjuvante continant une saponine et un oligonucleotide immunostimulateur | |
| WO2001035994A3 (fr) | Immunostimulation induite par le chitosane | |
| CU23305B7 (es) | Compuesto polisacã rido con actividad inmunoestimulante | |
| RU2002112709A (ru) | Способ предпосевной обработки семян |